GlassScriptPhysician profile
Andrew W Potler
NPI 1427149798
$651.45
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $596 · 2020: $55.19.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $227.70 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $75.20 | 2019 | |
| Janssen Pharmaceuticals, INC | $73.70 | 2019 | |
| Merck Sharp & Dohme LLC | $42.03 | 2019 | |
| Lilly USA, LLC | $39.21 | 2019 | |
| Pfizer INC. | $24.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.15 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.39 | 2019 | |
| Amgen INC. | $19.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.29 | 2019 | |
| Gilead Sciences, INC. | $12.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.25 | 2019 | |
| Novo Nordisk INC | $11.14 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11.02 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Potler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.